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Oxygen-radical regulation of renal blood flow
following suprarenal aortic clamping
Stuart I. Myers, MD, Li Wang, BS, Fang Liu, BS, and Lori L. Bartula, BS, Richmond, Va
Objective: Renal insufficiency continues to be complication that can affect patients after treatment for suprarenal
aneurysms and renal artery occlusive disease. One proposed mechanism of renal injury after suprarenal aortic clamping
(above the superior mesenteric artery) and reperfusion (SMA-SRACR) is the loss of microvascular renal blood flow with
subsequent loss of renal function. This study examines the hypothesis that the loss of medullary and cortical microvas-
cular blood flow following SMA-SRACR is due to oxygen-derived free radical down-regulation of endogenous medullary
and cortical nitric oxide synthesis.
Methods: Anesthetized male Sprague-Dawley rats (about 350 g) either had microdialysis probes or laser Doppler fibers
inserted into the renal cortex (depth of 2 mm) and into the renal medulla (depth of 4 mm). Laser Doppler blood flow was
continuously monitored. The microdialysis probes were connected to a syringe pump and perfused in vivo at 3 L/min
with lactated Ringer’s solution. The animals were subjected to SMA-SRACR (or sham) for 30 minutes, followed by 60
minutes of reperfusion. Laser Doppler blood flow after the 30 minutes of SMA-SRACR followed by 60 minutes of
reperfusion was compared with the time zero (basal) and with the corresponding sham group and reported as percent
change compared with the time zero baseline. Themicrodialysis fluid was collected at time zero (basal) and compared with
the dialysis fluid collected after 30 minutes of SMA-SRACR followed by 60 minutes of reperfusion as well as the
corresponding sham group. The microdialysis dialysate was analyzed for total nitric oxide (M) and prostaglandin E2
(PGE2), 6-keto-PGF1 (PGI2 metabolite), and thromboxane B2 synthesis. The data are reported as percent change
compared with the baseline time zero. The laser Doppler blood flow and microdialysis groups were treated with either
saline carrier, N-nitro-L-arginine methyl ester hydrochloride (L-NAME) (30 mg/kg, nitric oxide synthesis inhibitor),
L-arginine (400 mg/kg, nitric oxide precursor), superoxide dismutase (SOD, 10,000 U/kg, oxygen-derived free radical
scavenger), L-NAME  SOD, or L-arginine  SOD. SOD was given 30 minutes before the reperfusion, and the other
drugs were given 15 minutes before reperfusion. The renal cortex and medulla were separated and analyzed for inducible
nitric oxide synthase (iNOS), cyclooxygenase-2, prostacyclin synthase, and PGE2 synthase content by Western blot.
Results: Superior mesenteric artery-SRACR caused a marked decrease in medullary and cortical blood flow with a
concomitant decrease in endogenous medullary and cortical nitric oxide synthesis. These changes were further accentu-
ated by L-NAME treatment but restored toward sham levels by L-arginine treatment after SMA-SRACR. The kidney
appeared to compensate for these changes by increasing cortical and medullary PGE2 synthesis and release. SOD
treatment restored renal cortical and medullary nitric oxide synthesis and blood flow in the ischemia-reperfusion group
and in the ischemia-reperfusion group treated with L-NAME.
Conclusions: These data show that nitric oxide is important in maintaining renal cortical and medullary blood flow and
nitric oxide synthesis. These data also support the hypothesis that the loss of medullary and cortical microvascular blood
flow following SRACR is due in part to oxygen-derived free radical downregulation of endogenousmedullary and cortical
nitric oxide synthesis. ( J Vasc Surg 2006;43:577-86.)
Clinical Relevance: This study suggests that clinically relevant cortical and medullary vasodilators (nitric oxide and
vasodilator prostanoids) are required to maintain microvascular renal cortical and medullary blood flow. This study
combines in vivo techniques of microdialysis and laser Doppler flow probes to show that oxygen-derived free radicals are
one of the mediators that downregulate endogenous cortical and medullary nitric oxide synthesis, contributing to
decreased cortical and medullary blood flow that occurs in the SMA-SRACR model. Prevention or inhibition of
oxygen-derived free radical production during SMA-SRACR should be one of the treatment strategies that could help
maintain renal microvascular blood flow during the treatment of complex aortic pathology that requires SMA-SRACR.From the McGuire Research Institute/McGuire VA Medical Center and
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doi:10.1016/j.jvs.2005.10.051Renal dysfunction continues to be a frequent complica-
tion of suprarenal aortic reconstruction.1-3 A major limita-
tion to decreasing the incidence of renal dysfunction fol-
lowing suprarenal aortic clamping has been the lack of
insight into the pathophysiology of renal injury that occurs
after supra-SMA aortic clamping and reperfusion (SMA-
SRACR). Nitric oxide,4-10 prostaglandin E2 (PGE2) and I2
(PGI2) (vasodilator eicosanoids)
11-14 have been proposed
as important endogenous mediators that contribute to
arterial dilatation of the renal microvascular bed and main-
tenance of renal blood flow. Loss of these potent renal
vasodilators has been associated with renal vasoconstriction
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renal ischemia-reperfusion injury.15-22
Oxygen-derived free radicals (ODFRs) have been im-
plicated in the pathogenesis of renal injury induced by
ischemia-reperfusion.23 ODFRs have been proposed as
important mediators of renal tissue injury and are released
after ischemia-reperfusion injury and during the peroxidase-
catalyzed enzymatic reduction of hydroperoxy fatty acids
(endoperoxide). The highly reactive ODFRs inhibit eico-
sanoid and nitric oxide synthesis, which could lead to
decreased renal blood flow and function.23-26
We recently combined the use of in vivo microdialysis
and laser Doppler blood flow analyses to identify clinically
relevant intrarenal vasodilators (cortical and medullary)
that are required tomaintain microvascular blood flow after
SMA-SRACR. The findings of this study showed that
SMA-SRACR caused a profound decrease in medullary and
cortical blood flow with a concomitant decrease in endog-
enous medullary and cortical nitric oxide synthesis and
renal function.27 The mechanisms of these alterations in
renal physiology and function that follows SRACR are not
known. This study examines the hypothesis that the loss of
medullary and cortical microvascular blood flow following
SRACR is due to ODFR downregulation of endogenous
medullary and cortical nitric oxide synthesis.
MATERIALS AND METHODS
Animal model. All animal surgery and care was per-
formed according to the established guidelines approved
by the Institutional Animal Care and Use Committee, Vir-
ginia Commonwealth University/Medical College of Vir-
ginia and the McGuire VA Medical Center, Richmond,
Virginia.
Male Sprague-Dawley rats, weighing about 350 g
(Harlan, Indianapolis, Ind), were anesthetized with 2%
isoflurane vaporized by oxygen. The rats were placed on a
small-animal operating table with a fixed bar clamp holding
a Lucite kidney cup for isolation of the kidney from move-
ment. This allowed for precise placement of cortical and
medullary laser fiber probes with micropositioners. Micro-
dialysis catheters were also placed through the renal cortex
and medulla in separate groups.
The right femoral artery was cannulated, heparinized
(100 U/kg), and connected to a BPA blood pressure
analyzer (Digimed, Louisville, Ky) for constant monitoring
of heart rate and arterial blood pressure. Perivascular ultra-
sonic blood flow probes (Transonic Systems, Inc, Ithaca,
NY) were placed around the renal artery and the abdominal
aorta, and data were collected as milliliters per minute.
Body temperature was monitored by rectal temperature
probe. The animal’s abdomen was filled with saline and
lubricating jelly to insulate contact between blood flow
probes and blood vessels.
Either microdialysis probes or laser Doppler fibers were
inserted into the renal cortex (depth of 2 mm) and into
the renal medulla (depth of 4 mm) (see below for detail).
Both the laser Doppler blood flow andmicrodialysis groups
were treated with either saline carrier, N-nitro-L-argininemethyl ester hydrochloride (L-NAME) (30 mg/kg, nitric
oxide synthase inhibitor), L-arginine (400 mg/kg, nitric
oxide precursor), superoxide dismutase (SOD, 10,000U/kg,
ODFR), L-NAME  SOD, or L-arginine  SOD.17,28
SOD was given 30 minutes before the reperfusion, and the
other drugs were given 15 minutes before reperfusion. The
renal cortex and medulla were separated and analyzed for
inducible nitric oxide synthase (iNOS), cyclooxygenase 2
(COX-2), prostacyclin synthase, and PGE2 synthase con-
tent by Western blot (see below).
Microdialysis probes in vivo perfusion. Microdialysis
probes were prepared in advance to allow curing of the
epoxy and glue used to connect segments of PE-50 and
PE-10 tubing (Becton Dickinson, Sparks, Md), flexible
fused silica tubing (Polymicro Technologies, Phoenix, Ariz),
microdialysis tubing (13 kD transmembrane diffusion cut-
off tubing; Spectrum Laboratories, Rancho Dominquez,
Calif), and additional flexible fused silica tubing.29-31 One
microdialysis probe was inserted into the renal cortex to a
depth of 2 mm and another into the renal medulla at 4 mm.
These probes were connected to a syringe pump and per-
fused at a rate of 3 L/min with lactated Ringer’s solution.
Dialysate fluid was collected at basal time zero and after 30
minutes of aortic clamping above the superior mesenteric
artery (SMA-SRACR), followed by 60 minutes of reperfu-
sion, and compared with sham operation. Dialysate samples
were collected and frozen at –80oC until assayed for total
nitric oxide (M), PGE2, 6-keto-PGF1 (PGI2 metabolite)
and thromboxane B2 (thromboxane A2 metabolite) syn-
thesis. Data are reported as percent change of each sub-
stance after the 30 minutes of SMA clipping and 60 min-
utes of reperfusion compared with the baseline time zero.
Use of the microdialysis probes allowed nitric oxide,
PGE2, 6-keto-PGF1, and thromboxane B2 to diffuse in
and out of the dialysis probe, depending on the local
concentration. As nitric oxide and the eicosanoids mea-
sured are not stored within the cell, release of these sub-
stances represents de novo synthesis. After completion of
each experiment, the kidneys were opened to confirm
accurate placement of the microdialysis probes.
Laser Doppler renal cortical and medullary blood
flow analysis. The right kidney was isolated and placed in
a 21-mm Lucite kidney cup. Ultrasonic blood flow probes
(Transonic Systems, Inc) were placed around the renal
artery and abdominal aorta, and data were collected as
milliliters per minute. Body temperature was monitored by
a rectal probe. Micropositioners were used to insert the
shallow (2-mm cortical) and deep (4-mm medullary) cali-
brated laser fiber probes. Position of the fibers within the
kidneys was checked after each experiment. A Periflux 4001
Dual Channel Laser Doppler flowmeter (Perimed, Järfälla,
Sweden) was used to evaluate microvascular perfusion. Mea-
surements were expressed as arbitrary perfusion units, which
represent the product of the velocity and the concentration
of moving blood cells within the measuring volume. After a
5-minute equilibration period, basal readings were re-
corded, and subsequent readings were recorded every 10
minutes throughout the ischemia-reperfusion and sham
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cortical or medullary blood flow after the 30 minutes of
SMA clipping and 60 minutes of reperfusion compared
with the baseline time zero.
Enzyme immunoassays.15 The renal microdialysis ef-
fluent was frozen at –80oC until assayed for PGE2, 6-keto-
PGF1 and thromboxane B2 by an EIA enzyme immuno-
assay kit (Cayman Chemical, Ann Arbor, Mich). Samples
were run in duplicate and reported as picograms of eico-
sanoid per milliliter (mean  SEM). Data were converted
to percent change and compared with baseline at time zero.
Nitric oxide analysis. A Sievers 280 NOA Nitric Ox-
ide Analyzer with Radical Purger (Sievers Instruments,
Boulder, Colo) was used to detect nitric oxide (M) and its
reaction products in biologic samples. The technique used
for the measurement of nitric oxide and its oxidation prod-
ucts was the reduction of nitrate, nitrite, and nitrosothiol
using vanadium (III) and hydrochloric acid at 90oC.27 The
data are reported as percent change compared with the
baseline time zero.
Protein assays. The kidneys were harvested and
placed on ice. Cortical and medullary tissues were rapidly
separated, frozen in liquid nitrogen, and stored at –80oC
until assayed for protein. Tissues were thawed in a phos-
phate buffer, homogenized, and centrifuged at 4oC for 20
minutes. Supernatants were decanted, and total protein was
determined by the Bradford method32 utilizing the Bio-
Rad protein assay dye reagent concentrate (Bio-Rad Labo-
ratories, Hercules, Calif). A 5 sodium dodecyl sulfate
(SDS) sample buffer (1  62.5 mM Tris-hydrochloric
acid, pH 8.0; 2% SDS; 0.025% bromophenol blue; 20%
glycerol; 5% -mercaptoethanol) was added to the protein
samples and stored at –80oC until assayed by Western blot.
SDS-polyacrylamide gel electrophoresis and West-
ern blot analyses. Protein samples diluted in SDS sample
buffer were solubilized by boiling for 4 minutes. Aliquots
(25 g) were loaded into gel lanes of a vertical electro-
phoretic unit (Bio-Rad), and protein separation by molec-
ular weight was carried out on 1-mm 7% polyacrylamide
resolving gel with a 1-mm 3% stacking gel by the Laemmli
method,33 which includes prestained molecular weight
standard markers (Sigma-Aldrich Co., Milwaukee, WI).
Proteins were then transferred from the resolving gels
to nitrocellulose membranes (Schleicher & Schuell, Keene,
NH), as described by Burnette,34 using a Trans-Blot elec-
trophoretic transfer cell (Bio-Rad) operating at 100 mA for
18 hours at 4oC. The membranes were incubated for 1
hour at room temperature in blocking buffer (buffer B: 10
mM sodium phosphate, 0.5 M sodium chloride, 10% bo-
vine serum albumin, 0.05% Tween 20) and subsequently
overnight at room temperature in buffer B containing a
primary antibody,15,35 -COX-2 polyclonal antiserum (Cay-
man Chemical Co, Ann Arbor, Mich), PGE2 synthase (Cay-
manChemical Co), prostacyclin synthase (-prostacyclin syn-
thase polyclonal antiserum donated by Dr William Smith,
Michigan State University, East Lansing) or -inducible
nitric oxide synthase antiserum (Oxford Biomedical Re-
search, Inc., Oxford, Mich).The nitrocellulose membranes were washed of excess
primary antibody at room temperature in phosphate-
buffered saline Tween (PBST) (10 mM potassium phos-
phate, pH 7.4; 0.9% sodium chloride, 0.05% Tween 20)
and incubated for 1 hour at room temperature in buffer B
and secondary antibody, goat -rabbit immunoglobulin G
horseradish peroxidase (Bio-Rad). The membranes were
washed of secondary antibody at room temperature in
PBST, incubated in chemiluminescence reagent (Renais-
sance, DuPont-NEN, Boston, Mass) for 1 minute, inserted
into a plastic sheet protector, bubbles removed, and
placed against autoradiography film (Kodak, Rochester,
NY). The film exposure times were adjusted to obtain the
ideal density of bands identifying the enzymes of inter-
est, and an imaging system (Alpha Innotech, San Leandro,
Calif) was used to measure these bands by spot densitom-
etry.
Creatinine clearance. Separate groups of animals
were used to measure serum creatinine, urine creatinine,
Fig 1. The effect of supra-renal aortic clamping above the supe-
rior mesenteric artery and reperfusion on blood pressure (A) and
heart rate (B). The arterial blood pressure and heart rate were
continuously monitored at basal time period and after 30 minutes
followed by 60 minutes of reperfusion and compared with sham
operation. The ischemia/reperfusion (I/R) groups were treated
with saline carrier (I/R group, n  10), N-nitro-L-arginine
methyl ester hydrochloride (L-NAME) (30 mg/kg, nitric oxide
synthase inhibitor, n 8), or L-arginine (400 mg/kg, nitric oxide
precursor, n  8), with and without superoxide dismutase (SOD)
(10,000 U/kg, oxygen-derived free radical scavenger, n  8).
Data are reported as mmHg (A) and beats per minute (B) and are
expressed as mean  SEM; a indicates significance at P 	 .05
compared with sham and c indicates significance at P 	 .05
compared with L-NAME group.and urine volume.27 These groups underwent the same
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fusion as the above groups, but no microdialysis probes or
laser Doppler fibers were placed in the kidneys. These
groups underwent the sham and SMA-SRACR model with
saline carrier, L-NAME (30 mg/kg; nitric oxide synthase
inhibitor) or L-arginine (400 mg/kg, nitric oxide precur-
sor), superoxide dismutase (SOD, 10,000 U/kg, ODFR
scavenger), L-NAME  SOD or L-arginine  SOD (as
described above). Serum and urinary creatinine were mea-
sured by a SYNCHRON LC System (Beckman Coulter
Inc, Fullerton, Calif). Data are reported as milliliters per
minute.
Statistical analysis. The nitric oxide and eicosanoid
release data and the laser blood flow data were converted to
percent of original basal time to control for any intraexperi-
ment variation. Western blot data are expressed as densi-
tometry units, and the creatinine clearance is expressed as
milliliters per minute. The heart rate is expressed as beats
per min, and the blood pressure is reported as mean blood
pressure (mm Hg). All data are expressed as mean SEM.
An N of eight or more is used for all groups and specifically
identified in each figure legend. Analysis of variance and
Student’s t tests were used to determine differences among
the groups; a P 	 .05 value was considered statistically
Fig 2. The effect of supra-renal aortic clamping above the supe-
rior mesenteric artery (SMA) and reperfusion on renal cortical
blood flow. Laser Doppler probes were placed 2 mm into the
cortex, and blood flow was continuously monitored at basal time
period and after 30 minutes of supra-renal aortic clamping above
the SMA followed by 60 minutes of reperfusion and compared
with sham operation. The ischemia/reperfusion (I/R) groups
were treated with saline carrier (I/R group, n  10), N-nitro-L-
arginine methyl ester hydrochloride (L-NAME) (30 mg/kg, nitric
oxide synthase inhibitor, n 8), or L-arginine (400 mg/kg, nitric
oxide precursor, n  8) with and without superoxide dismutase
(SOD) (10,000 U/kg, oxygen-derived free radical scavenger, n
8). Data are reported as percent change from basal time zero and
expressed as mean  SEM; a indicates significance at P 	. 05
compared with sham, b indicates significance at P	 .05 compared
with the IR group without drug treatment, c indicates signifi-
cance at P 	 .05 compared with the L-NAME group, and
d indicates significance compared with the I/R  L-arginine
group at P 	 .05.significant.RESULTS
Superior mesenteric artery-SRACR did not signifi-
cantly alter mean blood pressure compared with the sham
group. L-NAME increased blood pressure, which was de-
creased with the addition of SOD treatment. L-arginine
decreased blood pressure compared with the sham, which
was partially reversed by treatment with SOD (Fig 1, A).
SMA-SRACR did not alter heart rate compared with the
sham group. Treatment of the SMA-SRACR or sham
groups with carrier, L-NAME or L-arginine (with and
without SOD) did not alter heart rate as well (Fig 1, B).
As shown before, SMA-SRACR profoundly decreased
renal cortical and medullary blood flow (Figs 2 and 3).
Treatment of the animals with L-NAME during SMA-
SRACR significantly decreased cortical and medullary
blood flow compared with the ischemia-reperfusion group
without drug treatment. Treatment of the animals with
L-arginine before SMA-SRACR significantly lessened the
decrease in cortical and medullary blood flow following
reperfusion compared with the ischemia-reperfusion and
L-NAME groups (Figs 2 and 3). This decrease in the fall of
blood flow was much more pronounced in the medulla
compared with the cortex (Figs 2 and 3). Pretreatment of
the SMA-SRACR groups with SOD significantly reversed
the fall in renal cortical and medullary blood flow in the
Fig 3. The effect of supra-renal aortic clamping above the supe-
rior mesenteric artery (SMA) and reperfusion on renal medullary
blood flow. Laser Doppler probes were placed 4 mm into the
medulla, and blood flow was continuously monitored at basal time
period and after 30 minutes of supra-renal aortic clamping above
the SMA followed by 60 minutes of reperfusion and compared
with sham operation. The ischemia/reperfusion (I/R) groups
were treated with saline carrier (I/R group, n  10), N-nitro-L-
arginine methyl ester hydrochloride (L-NAME) (30 mg/kg, nitric
oxide synthase inhibitor, n 8), or L-arginine (400 mg/kg, nitric
oxide precursor, n  8) with and without superoxide dismutase
(SOD) (10,000 U/kg, oxygen-derived free radical scavenger, n
8). Data are reported as percent change from basal time zero and
expressed as mean  SEM; a indicates significance at P 	 .05
compared with Sham, b indicates significance at P 	 .05 compared
with the I/Rgroupwithout drug treatment, c indicates significance at
P	 .05 compared with the L-NAME group, and d indicates signifi-
cance compared with the I/R L-arginine group at P	 .05.ischemia-reperfusion group and in the groups treated with
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group infused with L-arginine again reversed the fall in
cortical blood flow but did not alter medullary blood flow
in this group (Figs 2 and 3).
Nitric oxide release was markedly decreased after SMA-
SRACR in both the cortex and medulla. Both cortical and
medullary nitric oxide release was restored with SOD treat-
ment of the ischemia-reperfusion groups (Figs 4 and 5).
Treatment of the animals with L-NAME further decreased
cortical and medullary nitric oxide release, which was then
restored to the sham levels by SOD treatment. Treatment
of the ischemia-reperfusion groups with L-arginine re-
stored cortical but not medullary nitric oxide release to the
sham level. SOD treatment of the L-arginine groups in-
creased cortical and medullary nitric oxide release to above
sham levels (Figs 4 and 5).
Superior mesenteric artery-SRACR increased cortical
and medullary release of PGE2 compared with the sham
group (Fig 6, A and B). SOD treatment did not alter
cortical PGE2 release but increased medullary PGE2 release
fourfold compared with the sham group (Fig 6, A and B).
Treatment of the SMA-SRACR groups with L-NAME or
L-arginine did not alter PGE2 release in either the cortex or
medulla. Interestingly, treatment of the SMA-SRACR L-
Fig 4. The effect of supra-renal aortic clamping above the supe-
rior mesenteric artery (SMA) and reperfusion on renal cortical
nitric oxide release. Microdialysis probes were placed 2 mm into
the cortex, connected to a syringe pump, and perfused in vivo at
3 L/min with lactated Ringer’s solution. Dialysate fluid was
collected at basal time zero and after 30 minutes of supra-renal
aortic clamping above the SMA followed by 60 minutes of reper-
fusion and compared with sham operation. The ischemia/reperfu-
sion (I/R) groups were treated with saline carrier (I/R group, n
10), N-nitro-L-arginine methyl ester hydrochloride (L-NAME)
(30 mg/kg, nitric oxide synthase inhibitor, n  8), or L-arginine
(400 mg/kg, nitric oxide precursor, n  8) with and without
superoxide dismutase (SOD) (10,000 U/kg, oxygen-derived free
radical scavenger, n 8). Data are reported as percent change from
basal time zero and expressed as mean  SEM; a indicates signif-
icance at P 	 .05 compared with sham, b indicates significance at
P 	 .05 compared with the I/R group without drug treatment,
c indicates significance at P 	 .05 compared with the L-NAME
group, and d indicates significance compared with the I/R 
L-arginine group at P 	 .05.arginine group with SOD increased cortical PGE2 release2.5-fold compared with the L-arginine group without
SOD treatment (Fig 6, A). SMA-SRACR induced only
minor changes in cortical and medullary release of 6-keto-
PGF1 and thromboxane B2. SOD treatment did not alter
release of PGI2 or thromboxane B2 in any of the cortical or
medullary SMA-SRACR groups (Figs 7 and 8).
Superior mesenteric artery-SRACR decreased iNOS
and increased COX-2 content in the cortex but did not
alter medullary iNOS or COX-2 content (Fig 9). SMA-
SRACR did not alter cortical or medullary PGE2 synthase
or prostacyclin synthase content (Fig 10).
Superior mesenteric artery-SRACR caused a marked
decrease in the creatinine clearance compared with the
sham group. Treatment with either L-NAMEor L-arginine
did not alter creatinine clearance after SMA-SRACR. Ad-
dition of SOD to the SMA-SRACR group and to the
SMA-SRACR group treated with L-NAME did not alter
creatinine clearance. Addition of SOD to the SMA-SRACR
group treated with L-arginine did significantly increase
creatinine clearance compared with the SMA-SRACR
group treated with L-arginine alone (Fig 11).
DISCUSSION
Despite major advances in the treatment of suprarenal
Fig 5. The effect of supra-renal aortic clamping above the supe-
rior mesenteric artery (SMA) and reperfusion on renal medullary
nitric oxide release. Microdialysis probes were placed 4 mm into
the medulla, connected to a syringe pump, and perfused in vivo at
3 L/min with lactated ringer’s solution. Dialysate fluid was
collected at basal time zero and after 30 minutes of supra-renal
aortic clamping above the SMA followed by 60 minutes of reper-
fusion and compared with sham operation. The ischemia/reperfu-
sion (I/R) groups were treated with saline carrier (I/R group, n
10), N-nitro-L-arginine methyl ester hydrochloride (L-NAME)
(30 mg/kg, nitric oxide synthase inhibitor, n  8), or L-arginine
(400 mg/kg, nitric oxide precursor, n  8) with and without
superoxide dismutase (SOD) (10,000 U/kg, oxygen-derived free
radical scavenger, n 8). Data are reported as percent change from
basal time zero and expressed as mean  SEM; a indicates signif-
icance at P 	 .05 compared with sham, b indicates significance at
P 	 .05 compared with the I/R group without drug treatment,
c indicates significance at P 	 .05 compared with the L-NAME
group, and d indicates significance compared with the I/R 
L-Arginine group at P 	 .05.aneurysms, renal dysfunction continues to be a vexing
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dysfunction after repair of suprarenal aortic pathology is
that the pathophysiology of renal injury is not well under-
stood. Several animal studies have shown that suprarenal
aortic clamping (above the renal arteries) decreased total
renal artery blood flow, glomerular filtration rate (GFR),
urine flow, fractional sodium reabsorption, and caused an
increase in renal vascular resistance.36-38
Endogenous renal prostanoids have been hypothesized
to be potent mediators of renal vascular resistance for 
30
years.11-16 PGE2 and PGI2 are potent renal vasodilators,
and their decreased synthesis has been associated with renal
vasoconstriction.11-16 The loss of endogenous renal vaso-
dilators has been shown after a number of injuries, includ-
ing renal15-17 and intestinal ischemia-reperfusion inju-
Fig 6. The effect of supra-renal aortic clamping above the supe-
rior mesenteric artery and reperfusion on renal cortical (A) and
medullary (B) prostaglandin E2 (PGE2) release. Microdialysis
probes were placed 2 mm into the cortex, connected to a syringe
pump, and perfused in vivo at 3 L/min with lactated Ringer’s
solution. Dialysate fluid was collected at basal time zero and after
30minutes of supra-renal aortic clamping above the SMA followed
by 60 minutes of reperfusion and compared with sham operation.
The ischemia/reperfusion (I/R) groups were treated with saline
carrier (I/R group, n  10), N-nitro-L-arginine methyl ester
hydrochloride (L-NAME) (30mg/kg, nitric oxide synthase inhib-
itor, n 8), or L-arginine (400mg/kg, nitric oxide precursor, n
8) with and without superoxide dismutase (SOD) (10,000 U/kg,
oxygen-derived free radical scavenger, n 8). Data are reported as
percent change from basal time zero and expressed as mean 
SEM; a indicates significance at P 	 .05 compared with sham, b
indicates significance at P 	 .05 compared with the I/R group
without drug treatment, c indicates significance at P 	 .05 com-
pared with the L-NAME group, and d indicates significance com-
pared with the I/R  L-Arginine group at P 	 .05.ries.15,39,40Nitric oxide has been shown to contribute to the
maintenance of normal renal blood flow and function
under normal physiologic conditions,4-10 Loss of renal
nitric oxide synthesis has been suggested to contribute to
renal vasoconstriction following renal ischemia-reperfusion
injury.4-10,16,17,41 The importance of endogenous renal
nitric oxide in preserving renal function was supported by a
study that compared the effect of nitric oxide synthase
inhibition on renal function in both the in vitro and in vivo
perfused rat kidneymodels. Nitric oxide synthase inhibition
in the in vitro perfused rat kidney caused an increase in renal
vascular resistance, which was reversed by L-arginine infu-
sion. Nitric oxide synthesis inhibition in the in vivo kidney
model increased systemic arterial pressure, decreased GFR,
and decreased renal plasma flow.10 An in vivo microdialysis
technique was used to determine regional differences of
renal nitric oxide production. The results of this study
showed that nitric oxide was present in both renal cortex
Fig 7. The effect of supra-renal aortic clamping above the supe-
rior mesenteric artery (SMA) and reperfusion on renal cortical (A)
and medullary (B) prostaglandin I2 (PGI2) release. Microdialysis
probes were placed 4 mm into the medulla, connected to a syringe
pump, and perfused in vivo at 3 L/min with lactated Ringer’s
solution. Dialysate fluid was collected at basal time zero and after
30 minutes of suprarenal aortic clamping above the SMA followed
by 60 minutes of reperfusion and compared with sham operation.
The ischemia/reperfusion (I/R) groups were treated with saline
carrier (I/R group, n  10), N-nitro-L-arginine methyl ester
hydrochloride (L-NAME) (30mg/kg, nitric oxide synthase inhib-
itor, n 8), or L-arginine (400mg/kg, nitric oxide precursor, n
8) with and without superoxide dismutase (SOD) (10,000 U/kg,
oxygen-derived free radical scavenger, n 8). Data are reported as
percent change from basal time zero and expressed as mean 
SEM. PGI2 was measured as the stable metabolite 6-keto-PGF1.and medulla, with the highest nitric oxide concentration
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nitric oxide may play a role in the control of vascular tone
and tubular function in the renal medulla.41
The role of vasodilator eicosanoids and nitric oxide in
the regulation of renal blood flow following ischemia-
reperfusion injury is not known. Several studies have exam-
ined the hypothesis that renal ischemia decreases renal
blood flow and endogenous renal vasodilator eicosanoids
and nitric oxide, which in turn contributes to further renal
vasoconstriction. Inhibition of COX or nitric oxide syn-
thase was shown to increase renal vascular resistance after
renal ischemia and reperfusion, implying that vasodilator
eicosanoids and nitric oxide were important mediators in-
volved withmaintenance of renal blood flow after ischemia-
reperfusion injury.16
A second group of studies suggested that acute renal
Fig 8. The effect of supra-renal aortic clamping above the supe-
rior mesenteric artery (SMA) and reperfusion on renal cortical (A)
and medullary (B) thromboxane B2 (TxB2) release. Microdialysis
probes were placed 4 mm into the medulla, connected to a syringe
pump, and perfused in vivo at 3 L/min with lactated Ringer’s
solution. Dialysate fluid was collected at basal time zero and after
30minutes of supra-renal aortic clamping above the SMA followed
by 60 minutes of reperfusion and compared with sham operation.
The ischemia/reperfusion (I/R) groups were treated with saline
carrier (I/R group, n  10), N-nitro-L-arginine methyl ester
hydrochloride (L-NAME) (30mg/kg, nitric oxide synthase inhib-
itor, n 8), or L-arginine (400mg/kg, nitric oxide precursor, n
8) with and without superoxide dismutase (SOD) (10,000 U/kg,
oxygen-derived free radical scavenger, n  8). Thromboxane A2
measured as the stable metabolite thromboxane B2 (TxB2); a
indicates significance at P 	 .05 compared with sham, and
d indicates significance compared with the I/RL-arginine group
at P 	 .05.injury induces changes in blood flow away from the deepcortex and outer medulla, thus altering renal function as
well as water and salt excretion.13,14,18-22 There is no litera-
ture regarding the effects of renal ischemia-reperfusion after
suprarenal aortic clamping or SMA-SRACR on regional
blood flow within the kidney.
Oxygen-derived free radicals have been implicated in
the pathogenesis of renal ischemia-reperfusion injury. Dur-
ing the phase of ischemia, hypoxanthine and xanthine are
produced after degradation of adenosine triphosphate, and
xanthine dehydrogenase is converted to xanthine oxi-
dase.23,42,43 During the reperfusion phase, molecular oxy-
gen purines are metabolized by xanthine oxidase, leading
Fig 9. The effect of supra-renal aortic clamping above the supe-
rior mesenteric artery and reperfusion (SMA-SPACR) on renal
cortical and medullary inducible nitric oxide synthase (iNOS) and
cyclooxygenase 2 (COX-2) content. Protein from renal cortex and
medulla was prepared from sham and SMA-SRACR animals
and subjected to Western blot analysis to identify content of iNOS
and COX-2. The blots were analyzed by densitometry. Data are
expressed as densitometry units  SEM (n  8); a indicates
significance at P 	 .05 compared with sham.
Fig 10. The effect of supra-renal aortic clamping above the supe-
rior mesenteric artery and reperfusion (SMA-SRACR) on renal
cortical and medullary prostaglandin E2 synthase (E2) and prosta-
cyclin synthase (PS) content. Protein from renal cortex and me-
dulla was prepared from sham and SMA-SRACR animals and
subjected to Western blot analysis to identify E2 and PS content.
The blots were analyzed by densitometry. Data are expressed as
densitometry units  SEM (n  8).to superoxide radical production. This may then be con-
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graded to water and oxygen by the enzyme catalase. Super-
oxide anions can also react with hydrogen peroxide in the
presence of iron to form the highly reactive hydroxyl radi-
cals. All of the ODFR species can react with protein, nucleic
acids, or lipids, leading to renal damage.23,42,43 A number
of studies have used SOD, copper-zinc (CuZn) SOD,
N-acetyl cysteine, or a CuZn-SOD gene to attenuate or
reverse renal injury following renal ischemia-reperfusion
injury.44-48
The studies noted above have not examined the role of
nitric oxide, vasodilator eicosanoids, or ODFRs in the
regulation of renal blood flow after SMA-SRACR. Our
laboratory has recently combined the techniques of in vivo
microdialysis and laser Doppler blood flow to investigate,
for the first time, real-time changes in renal cortical and
medullary blood flow, nitric oxide, and PGE2 synthesis
after SMA-SRACR. The results of our earlier study showed
that SMA-SRACR caused a marked decrease in medullary
and cortical blood flow, with a concomitant decrease in
endogenous medullary and cortical nitric oxide synthesis
and serum creatinine clearance. The addition of indometh-
acin, a COX inhibitor, caused a concomitant decrease in
medullary and cortical PGE2 synthesis and blood flow.
27
The current study corroborates the findings of our
Fig 11. The effect of supra-renal aortic clamping above the supe-
rior mesenteric artery (SMA) and reperfusion on creatinine clearance
(CrCl). Serum and urine were collected from separate groups of
animals to measure serum creatinine, urine creatinine, and urine
volume to calculate creatinine clearance. The serum and urine were
collected at basal time zero and after 30 minutes of supra-renal
aortic clamping above the SMA followed by 60 minutes of reper-
fusion and compared to with sham operation. The ischemia/
reperfusion (I/R) groups were treated with saline carrier (I/R
group, n  10), N-nitro-L-arginine methyl ester hydrochloride
(L-NAME) (30 mg/kg, nitric oxide synthase inhibitor, n 8), or
L-arginine (400 mg/kg, nitric oxide precursor, n  8) with and
without superoxide dismutase (SOD) (10,000 U/kg, oxygen-
derived free radical scavenger, n  8). Data are reported as mL/
min (mean  SEM; a indicates significance at P 	 .05 compared
with sham, b indicates significance at P 	 .05 compared with the
I/R group without drug treatment, c indicates significance at P 	
.05 compared with the L-NAME group, and d indicates signifi-
cance compared with the I/R  L-arginine group at P 	 .05.previous study. SMA-SRACR caused a marked decrease inmedullary and cortical blood flow with a concomitant
decrease in endogenous medullary and cortical nitric oxide
synthesis. These changes were further accentuated by treat-
ment with L-NAME, an iNOS inhibitor. Treatment of the
animals with L-arginine, an nitric oxide agonist, restored
medullary blood flow toward sham levels but did not alter
cortical or medullary nitric oxide release or cortical blood
flow after SMA-SRACR. The decrease in cortical iNOS
content that follows SMA-SRACR may in part be one of
the mechanisms whereby L-arginine treatment could not
reverse the profound decrease in cortical blood flow com-
pared with the medulla.
The kidney appeared to compensate for the decreased
cortical and medullary nitric oxide and blood flow by
increasing the cortical and medullary vasodilator PGE2
release. The mechanism of the increased PGE2 release
appears to be different for the cortex and medulla. In-
creased PGE2 release in the cortex was associated with
increased content of COX-2, which suggests an upregula-
tion of COX-2 in the cortex after SMA-SRACR (Fig 10).
The increased PGE2 release in the medulla after SMA-
SRACR was not associated with an increase in COX-2 or
PGE2 synthase.
This finding suggests an increase in activity in either (or
both) COX-2 or PGE2 synthase in the medulla following
SMA-SRACR and was not secondary to a change in con-
tent as was demonstrated in the cortex. These findings
suggest that the cortex and medulla have different mecha-
nisms responsible for increased PGE2 release after SMA-
SRACR. SMA-SRACR did not alter thromboxane or pros-
tacyclin synthesis, suggesting that these eicosanoids are not
major factors contributing to the regulation of renal corti-
cal or medullary blood flow in this model.
Superoxide dismutase treatment restored renal cortical
and medullary nitric oxide synthesis over sham levels and
restored cortical and medullary blood flow to 75% of sham
levels after SMA-SRACR. SOD treatment combined with
L-NAME prevented 50% of the decrease in cortical and
medullary blood flow and nitric oxide release compared
with the groups treated with L-NAME alone. SOD treat-
ment combined with L-arginine reversed cortical blood
flow almost to the sham level, whereas SOD treatment
combined with L-arginine did not further improve medul-
lary blood flow seen after L-arginine treatment alone fol-
lowing SMA-SRACR. These findings suggest that the re-
sponse of the cortex and medulla in terms of nitric oxide
synthesis and changes in blood flow are different after
inhibition of ODFRs, with the cortex most affected by
ODFRs. The incomplete reversal of cortical and medullary
blood flow by SOD treatment suggests that other factors
are involved with the regulation of blood flow within the
kidney after SMA-SRACR (see following).
Superior mesenteric artery-SRACR profoundly de-
creased creatinine clearance, which was not reversed by
L-arginine or SOD treatment in any of the experimental
groups. This finding suggests that clamping the aorta above
the SMA for 30 minutes is a severe physiologic insult to the
kidney, and factors other than those investigated in the
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that follows SMA-SRACR. These data suggest that we
need to expand the scope of our studies to investigate and
determine the other inflammatory mediators that contrib-
ute to the loss of endogenous renal nitric oxide, blood flow,
and function so that treatment regimens can be designed to
help lessen the incidence and extent or renal dysfunction
following SMA-SRACR.
The incomplete reversal of the profound decreases in
cortical and medullary blood flow following SMA-SRACR
by SOD treatment shows this study has several limitations.
The use of SOD, although providing the first insight into
superoxide radical regulation of cortical and medullary
blood flow following SMA-SRACR, does not address the
role of other oxygen radical species in this model. For
example, further studies are needed to define the role of
hydroxyl radicals in this system.
A second limitation is the use of male animals and,
therefore, the study does not investigate if the changes
found are effected by sex.
A third limitation is the placement of the aortic clamp
above the SMA and not the celiac artery (supraceliac artery
clamping is more commonly used in our patients). Supra-
SMA clamping in the rat is quite easy and avoids manipu-
lation of the viscera (especially the liver), whereas suprace-
liac clamping is difficult, requires manipulation of the
viscera, and involves more time and trauma to the animal.
CONCLUSION
This study supports the notion that nitric oxide is
important in maintaining renal cortical and medullary
blood flow and function. These data also support the
hypothesis that the loss of medullary and cortical microvas-
cular blood flow following SMA-SRACR is partly due to
ODFRdownregulation of endogenous renal medullary and
cortical nitric oxide synthesis. These data also suggest that
we need to expand the scope of our studies to determine
the other inflammatory mediators and ODFR species that
contribute to the loss of endogenous renal nitric oxide,
blood flow, and function following SMA-SRACR. Identi-
fication of factors responsible for maintaining renal micro-
vascular blood flow will allow development of treatment
strategies that will help maintain renal microvascular blood
flow in the treatment of complex aortic pathology that
requires suprarenal aortic clamping during the aortic recon-
struction.
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